SP110抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: LOVO cell lysate, Primary antibody: P10563(SP110 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10563(SP110 Antibody) at dilution 1/135. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10563(SP110 Antibody) at dilution 1/135. (Original magnification: ×200)    

  
  

The SP110 antibody targets the SP110 protein, a nuclear body protein encoded by the *SP110* gene. SP110 belongs to the SP100 family, known for roles in transcriptional regulation and innate immunity. It is implicated in antiviral defense, chromatin remodeling, and cell differentiation. Structurally, SP110 contains a SAND domain (involved in DNA binding), a PHD finger (linked to chromatin modification), and a bromodomain (acetyl-lysine recognition), suggesting its involvement in epigenetic regulation.

SP110 gained attention due to its association with human diseases. Studies link *SP110* polymorphisms to susceptibility to tuberculosis (TB), highlighting its role in immune responses against *Mycobacterium tuberculosis*. Additionally, SP110 dysregulation is observed in cancers, particularly acute myeloid leukemia (AML), where it may act as a tumor suppressor or oncogene depending on context.

Antibodies against SP110 are critical tools for detecting its expression, localization, and post-translational modifications in research. They are used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study SP110's role in immune pathways, host-pathogen interactions, and cancer biology. Commercial SP110 antibodies are typically validated in human and mouse models, aiding mechanistic studies in infectious and neoplastic diseases. Ongoing research explores SP110 as a potential biomarker or therapeutic target, emphasizing its dual relevance in immunology and oncology.